Stock ARDS ARIDIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Market Closed - OTC Markets
Other stock markets
 19:07:52 26/04/2024 BST 		5-day change 1st Jan Change
0.065 USD 0.00% Intraday chart for Aridis Pharmaceuticals, Inc. +8.33% -7.28%
2023 Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI

Evolution of the average Target Price on Aridis Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

00e.gpO9ypXohg4yZ_zCOt8PMIacX8IxKL1_M3zznpDUeDI.1_HcoeyK0z1xFI-0TrdbSM2uMrpJbsQ3VyWQysG7N3XL0v_90LzzfAAoyA~32dbfd91b284d0b4814d954eb1265b0d

Analyst Recommendations on Aridis Pharmaceuticals, Inc.

HC Wainwright Adjusts Aridis Pharmaceuticals' Price Target to $10 From $19, Keeps Buy Rating MT
Maxim Downgrades Aridis Pharmaceuticals to Hold From Buy MT
Northland Securities Adjusts Aridis Pharmaceuticals PT to $10 From $22, Maintains Outperform Rating MT
ARIDIS PHARMACEUTICALS : HC Wainwright Adjusts Aridis Pharmaceuticals' Price Target to $19 From $11, Reiterates Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.065 USD
Average target price
2 USD
Spread / Average Target
+2,976.92%
High Price Target
2 USD
Spread / Highest target
+2,976.92%
Low Price Target
2 USD
Spread / Lowest Target
+2,976.92%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Aridis Pharmaceuticals, Inc.

HC Wainwright
Maxim
Northland Securities

Ratings for Aridis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ARDS Stock
  4. Consensus Aridis Pharmaceuticals, Inc.